A new pill versus crizotinib for first treatment of ALK-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new pill (SY-3505) compared to the standard first treatment (crizotinib) for people with ALK-positive advanced lung cancer that hasn't been treated yet. If you qualify, you'd be randomly assigned to one of these two oral medicines, and the study will see which one works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have stage 4 or stage 3B/3C lung cancer that can't be cured with surgery or radiation.
- You have not received any prior drug treatment for your lung cancer, or you've had at most 1 round of chemotherapy. If you had surgery/radiation before, it must have been at least 6 months ago.
- Your tumor or blood test shows you have the ALK gene change (ALK-positive).
- You have at least one tumor outside the brain that can be measured on scans.
- You are able to perform daily activities on your own (performance status 0-2) and have adequate organ function (kidney, liver, bone marrow).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether ALK-targeted drugs can shrink or control advanced squamous cell cancer that has spread. You may be eligible if your tumor has an ALK gene rearrangement and you have not had prior cancer medicines for this stage.
This study tests a new pill called neladalkib to see if it works better than the current standard treatment (alectinib) for people with ALK-positive lung cancer who have not yet received any cancer therapy for advanced disease. It may be a good option if you have ALK-positive NSCLC and have not been treated before.
This study compares a new targeted therapy pill (taletrectinib) to standard treatments for people with advanced ROS1-positive lung cancer. The goal is to see if taletrectinib works better at shrinking tumors and delaying cancer growth.
This study tests whether adding focused radiation to a targeted cancer pill works better than the pill by itself. It is for people with advanced non-small cell lung cancer (NSCLC) whose tumor has an EGFR or ALK/ROS driver mutation and who have not gotten worse after starting the targeted pill.
This trial compares a new targeted therapy pill (firmanertinib) to standard chemotherapy in people with advanced non-small cell lung cancer whose tumors have a specific EGFR mutation (PACC or L861Q). If you haven't had treatment for advanced disease and your cancer matches these mutations, this study may offer a more convenient oral option.
This study tests two targeted pills, crizotinib and alectinib, for people with advanced bone cancer that has a specific gene change called ALK. These medicines block the ALK protein, which may help shrink or slow the cancer if standard treatments have stopped working.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.